EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:OCEA),(NASDAQ:LVTX),(NYSE:MRK),(NYSE:ABBV) EQNX::TICKER_END
Geron (GERN) delivered earnings and revenue surprises of 22.22% and 85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -37.50% and 59.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...
iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 35.71% and 30.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...
Curis (CRIS) delivered earnings and revenue surprises of 14.29% and 4.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
The mean of analysts' price targets for LAVA Therapeutics N.V. (LVTX) points to a 197.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...
LAVA Therapeutics N.V. (LVTX) delivered earnings and revenue surprises of 157.14% and 38.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...
LAVA Therapeutics N.V. (LVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of 1.15% and 131.59%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...